Analysis of 271 drugs competing for the new version of the medical insurance catalogue: The opportunities for listed drugs before 2016 are elusive, and monoclonal antibodies and tinib are still active

Outlook: The adjustment of the medical insurance catalog in 2021 is imminent.

From 9:00 on July 1, 2021 to 17:00 on July 14, 2021, a total of 501 pieces of enterprise application information were received, involving 474 drugs

Comparing the 2020 and 2021 National Medical Insurance Drug Catalog Adjustment Work Plan and the National Medical Insurance Drug Catalog Adjustment Approved Drug List Passed Formal Examination, it is found that although the 2021 version still includes the treatment of respiratory diseases related to new coronary pneumonia into the entry In the path of the medical insurance catalog, but no product can pass the formal review

The adjustment of the National Medical Insurance Drug List in 2021 will no longer encourage "inclusion in the "List of Urgently Needed Overseas New Drugs (First Batch)", "List of Urgently Needed Overseas New Drugs (Second Batch)", "List of First Batch of Encouraged Generic Drugs", The First Batch of Drugs Encouraged to R&D and Application for Children's Drug List" or "The Third Batch of Drugs to Encourage Research and Development to Apply for Children's Drug List", and the drugs approved for marketing by the State Drug Administration before August 17, 2020" and the "Second Batch of National Organizations for Centralized Procurement of Drugs" "Selected drugs", to a certain extent, means that generic drugs whose generic names have not been included in the medical insurance are basically difficult to enter the medical insurance list, unless their indications or functions and indications undergo major changes or they are the first generic drugs

The 6 products that entered the review list on the grounds of the National Essential Drug List are also products that entered the review list in 2020 for the same reason, namely Citicoline Sodium Chloride Injection, Citicoline Sodium Glucose Injection , Compound Potassium Hydrogen Phosphate Injection, Isosorbide Nitrate Sodium Chloride Injection, Isosorbide Nitrate Glucose Injection and Tang Herb Tablets

There are 79 varieties of Western medicines and proprietary Chinese medicines out of the catalog that were not included in the medical insurance catalog last year and continued to work hard this year, including monoclonal antibodies such as Alixizumab injection, Emeicilizumab injection, Daletto Usumab injection, duvalizumab injection, nivoliuzumab injection, pembrolizumab injection, pecelizumab injection, usnumab injection/Uss Numab injection (intravenous infusion), iloyuumab injection and ichilizumab injection, two tinib products, dacotinib tablets and neratinib maleate tablets, in addition to Including ibuprofen injection, a large product originally developed and not marketed in China

Otuzumab injection, brozoyuumab injection, ranaliyuumab injection, ipilimumab injection, belintuzumab for injection, and verbutuximab for injection Antibodies are all newly added monoclonal antibodies in 2021

Data source: Xianda Yaohai Database

Combined with the CDE drug review report in 2020, a total of 20 innovative drugs have been reviewed by the Center for Drug Evaluation in 2020, and a total of 11 have entered the medical insurance form review

Note:

1.